Cartcentric Diagnostics is categorized under Commercial Biotechnical Research in Philadelphia, PA and active since 2012.
Cartcentric Diagnostics was established in 2012, and today employs 1 to 4, earning $0 to $49.999 per year. This is a Commercial Biotechnical Research business, which does work in the B2B market, and is classified as a Commercial Biotechnical Research, under code number 541711 by the NAICS.
If you are seeking more information, feel free to contact Steven Davis at the company’s single location by writing to 3160 Chestnut St # 200, Philadelphia, Pennsylvania PA 19104 or by phoning (215) 219-9152. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Cartcentric Diagnostics |
| Contact Person: | Steven Davis |
| Address: | 3160 Chestnut St # 200, Philadelphia, Pennsylvania 19104 |
| Phone Number: | (215) 219-9152 |
| Annual Revenue (USD): | $0 to $49.999 |
| Founded: | 2012 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Biotechnical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541711 |
| Share This Business: |
Cartcentric Diagnostics was started in 2012 to provide professional Commercial Biotechnical Research under the SIC code 8731 and NAICS code 541711. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $0 to $49.999 per annum.
Feel free to contact Steven Davis for inquiries that concern Cartcentric Diagnostics by calling the company number (215) 219-9152, as your correspondence is most welcome. Additionally, the physical location of the single location of Cartcentric Diagnostics can be found at the coordinates 39.953553,-75.18659 as well as the street address 3160 Chestnut St # 200 in Philadelphia, Pennsylvania 19104.
For its online presence, you may visit Cartcentric Diagnostics’s website at and engage with its social media outlets through on Twitter and on Facebook.